Titre : Phylogenèse

Phylogenèse : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Phylogenèse : Questions médicales les plus fréquentes", "headline": "Phylogenèse : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Phylogenèse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-29", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Phylogenèse" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Sciences de l'information", "url": "https://questionsmedicales.fr/mesh/D007254", "about": { "@type": "MedicalCondition", "name": "Sciences de l'information", "code": { "@type": "MedicalCode", "code": "D007254", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "L01" } } }, "about": { "@type": "MedicalCondition", "name": "Phylogenèse", "alternateName": "Phylogeny", "code": { "@type": "MedicalCode", "code": "D010802", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Josef Vlasák", "url": "https://questionsmedicales.fr/author/Josef%20Vlas%C3%A1k", "affiliation": { "@type": "Organization", "name": "Biology Centre, Czech Academy of Sciences, Institute of Plant Mol. Biol., Branišovská 31, CZ-370 05 České Budějovice, Czech Republic Biology Centre, Czech Academy of Sciences České Budějovice Czech Republic." } }, { "@type": "Person", "name": "Yu-Cheng Dai", "url": "https://questionsmedicales.fr/author/Yu-Cheng%20Dai", "affiliation": { "@type": "Organization", "name": "School of Ecology and Nature Conservation, Beijing Forestry University, Beijing 100083, China Beijing Forestry University Beijing China." } }, { "@type": "Person", "name": "Shu-Yan Liu", "url": "https://questionsmedicales.fr/author/Shu-Yan%20Liu", "affiliation": { "@type": "Organization", "name": "a Laboratory of Plant Pathology, College of Plant Protection, Jilin Agricultural University." } }, { "@type": "Person", "name": "Michael Bradshaw", "url": "https://questionsmedicales.fr/author/Michael%20Bradshaw", "affiliation": { "@type": "Organization", "name": "c Harvard University, Department of Organismic and Evolutionary Biology." } }, { "@type": "Person", "name": "Uwe Braun", "url": "https://questionsmedicales.fr/author/Uwe%20Braun", "affiliation": { "@type": "Organization", "name": "d Martin Luther University, Institute of Biology, Geobotany and Botanical Garden, Herbarium." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.", "datePublished": "2023-01-13", "url": "https://questionsmedicales.fr/article/36651430", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb371205" } }, { "@type": "ScholarlyArticle", "name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36253300", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clgc.2022.09.007" } }, { "@type": "ScholarlyArticle", "name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.", "datePublished": "2024-10-20", "url": "https://questionsmedicales.fr/article/39428439", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-76355-4" } }, { "@type": "ScholarlyArticle", "name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.", "datePublished": "2023-05-26", "url": "https://questionsmedicales.fr/article/37271051", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cmpb.2023.107624" } }, { "@type": "ScholarlyArticle", "name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36917412", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11255-023-03531-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Sciences de l'information", "item": "https://questionsmedicales.fr/mesh/D007254" }, { "@type": "ListItem", "position": 3, "name": "Phylogenèse", "item": "https://questionsmedicales.fr/mesh/D010802" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Phylogenèse - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Phylogenèse", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Phylogenèse", "description": "Comment déterminer la phylogénie d'une espèce ?\nQuels outils sont utilisés en phylogénie ?\nQu'est-ce qu'un arbre phylogénétique ?\nQuelle est l'importance de la phylogénie ?\nComment la phylogénie aide-t-elle en médecine ?", "url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Phylogenèse", "description": "Quels symptômes peuvent indiquer une évolution rapide ?\nComment les symptômes évolutifs se manifestent-ils ?\nLes symptômes peuvent-ils être liés à la phylogénie ?\nQuels symptômes sont observés chez les espèces en danger ?\nComment les symptômes évolutifs influencent-ils la survie ?", "url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Phylogenèse", "description": "Comment la phylogénie contribue-t-elle à la prévention des maladies ?\nQuels rôles jouent les études phylogénétiques en santé publique ?\nComment prévenir la propagation des pathogènes ?\nLa phylogénie peut-elle aider à prévenir les zoonoses ?\nQuels sont les défis de la prévention basée sur la phylogénie ?", "url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Phylogenèse", "description": "Comment la phylogénie influence-t-elle les traitements médicaux ?\nQuels traitements sont basés sur la phylogénie ?\nLa phylogénie aide-t-elle à la découverte de médicaments ?\nQuels sont les défis des traitements basés sur la phylogénie ?\nComment la phylogénie aide-t-elle à prévenir les résistances ?", "url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Phylogenèse", "description": "Quelles complications peuvent survenir en cas d'évolution rapide ?\nComment la phylogénie aide-t-elle à comprendre les complications ?\nQuelles complications sont liées aux infections virales ?\nLes complications peuvent-elles être prédites par la phylogénie ?\nComment gérer les complications liées à la phylogénie ?", "url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Prostatic+Neoplasms&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Phylogenèse", "description": "Quels facteurs de risque influencent l'évolution des pathogènes ?\nComment l'environnement affecte-t-il la phylogénie ?\nQuels comportements augmentent les risques d'infection ?\nLes voyages influencent-ils la phylogénie des maladies ?\nComment la biodiversité affecte-t-elle les risques de maladies ?", "url": "https://questionsmedicales.fr/mesh/D010802?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment déterminer la phylogénie d'une espèce ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "On utilise des analyses génétiques et morphologiques pour établir des relations évolutives." } }, { "@type": "Question", "name": "Quels outils sont utilisés en phylogénie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les outils incluent les arbres phylogénétiques et les logiciels de bioinformatique." } }, { "@type": "Question", "name": "Qu'est-ce qu'un arbre phylogénétique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "C'est une représentation graphique des relations évolutives entre différentes espèces." } }, { "@type": "Question", "name": "Quelle est l'importance de la phylogénie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle aide à comprendre l'évolution des espèces et leur adaptation à l'environnement." } }, { "@type": "Question", "name": "Comment la phylogénie aide-t-elle en médecine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de tracer l'origine des pathogènes et d'identifier des cibles thérapeutiques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une évolution rapide ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des changements rapides dans les traits d'une population peuvent signaler une évolution." } }, { "@type": "Question", "name": "Comment les symptômes évolutifs se manifestent-ils ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent se manifester par des variations morphologiques ou comportementales." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être liés à la phylogénie ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains symptômes peuvent être hérités et refléter des relations évolutives." } }, { "@type": "Question", "name": "Quels symptômes sont observés chez les espèces en danger ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes de stress, de déclin de la reproduction et de perte de diversité peuvent apparaître." } }, { "@type": "Question", "name": "Comment les symptômes évolutifs influencent-ils la survie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent affecter l'adaptation et la capacité de survie dans un environnement changeant." } }, { "@type": "Question", "name": "Comment la phylogénie contribue-t-elle à la prévention des maladies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Elle aide à identifier les souches pathogènes et à développer des stratégies de vaccination." } }, { "@type": "Question", "name": "Quels rôles jouent les études phylogénétiques en santé publique ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent de surveiller les épidémies et de comprendre la transmission des maladies." } }, { "@type": "Question", "name": "Comment prévenir la propagation des pathogènes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "En utilisant des données phylogénétiques pour cibler les interventions de santé publique." } }, { "@type": "Question", "name": "La phylogénie peut-elle aider à prévenir les zoonoses ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle permet d'identifier les espèces réservoirs et de réduire les risques de transmission." } }, { "@type": "Question", "name": "Quels sont les défis de la prévention basée sur la phylogénie ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les changements rapides des pathogènes peuvent compliquer les efforts de prévention." } }, { "@type": "Question", "name": "Comment la phylogénie influence-t-elle les traitements médicaux ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de développer des traitements ciblés basés sur les relations évolutives des pathogènes." } }, { "@type": "Question", "name": "Quels traitements sont basés sur la phylogénie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccins et les thérapies géniques peuvent être développés en tenant compte de la phylogénie." } }, { "@type": "Question", "name": "La phylogénie aide-t-elle à la découverte de médicaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle guide la recherche de nouvelles molécules en identifiant des cibles évolutives." } }, { "@type": "Question", "name": "Quels sont les défis des traitements basés sur la phylogénie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les variations génétiques rapides des pathogènes peuvent rendre les traitements moins efficaces." } }, { "@type": "Question", "name": "Comment la phylogénie aide-t-elle à prévenir les résistances ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'anticiper les mutations et d'adapter les traitements pour éviter les résistances." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir en cas d'évolution rapide ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des résistances aux traitements et des épidémies peuvent survenir en raison d'évolutions rapides." } }, { "@type": "Question", "name": "Comment la phylogénie aide-t-elle à comprendre les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet d'analyser les relations entre les souches et les complications associées." } }, { "@type": "Question", "name": "Quelles complications sont liées aux infections virales ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les infections virales peuvent entraîner des complications respiratoires et neurologiques." } }, { "@type": "Question", "name": "Les complications peuvent-elles être prédites par la phylogénie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en étudiant les relations évolutives, on peut prédire certaines complications potentielles." } }, { "@type": "Question", "name": "Comment gérer les complications liées à la phylogénie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance continue et des ajustements de traitement sont essentiels pour gérer les complications." } }, { "@type": "Question", "name": "Quels facteurs de risque influencent l'évolution des pathogènes ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les mutations génétiques, l'environnement et les interactions hôtes-pathogènes sont cruciaux." } }, { "@type": "Question", "name": "Comment l'environnement affecte-t-il la phylogénie ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les changements environnementaux peuvent favoriser certaines adaptations et influencer l'évolution." } }, { "@type": "Question", "name": "Quels comportements augmentent les risques d'infection ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Des comportements comme le non-respect des mesures d'hygiène et la surpopulation augmentent les risques." } }, { "@type": "Question", "name": "Les voyages influencent-ils la phylogénie des maladies ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyages facilitent la propagation des souches et augmentent le risque d'épidémies." } }, { "@type": "Question", "name": "Comment la biodiversité affecte-t-elle les risques de maladies ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Une biodiversité élevée peut réduire les risques de maladies en limitant la transmission entre espèces." } } ] } ] }

Sources (10000 au total)

Presence of HPV in prostate tissue from patients submitted to prostate biopsy.

Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat... Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus.... Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ... There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....

Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.

In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals.... This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ... It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high... As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...

Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.

With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di... We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ... An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve... This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...

Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.

To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n... The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit... In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ... A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o... PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u... More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ... Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....

Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?

Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga... Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu... Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114... The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...